Vaxcyte (PCVX) Receivables - Other (2022 - 2025)

Vaxcyte (PCVX) has 4 years of Receivables - Other data on file, last reported at $21.4 million in Q4 2025.

• On a quarterly basis, Receivables - Other rose 5.4% year-over-year to $21.4 million in Q4 2025; TTM through Dec 2025 was $21.4 million, a 5.4% increase from a year earlier, with the FY2025 full-year figure at $21.4 million, up 5.4% from the prior year.
• Receivables - Other for Q4 2025 stood at $21.4 million, up from $20.3 million in the prior quarter.
• Over the last five years, Receivables - Other for PCVX reached as high as $21.4 million in Q4 2025 and fell as low as $2.8 million in Q4 2022.
• Historically, Receivables - Other has averaged $10.6 million across 4 years, with a median of $8.0 million in 2024.
• Across the five-year window, Receivables - Other jumped 463.15% in 2024 and rose 5.4% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $2.8 million in 2022, then grew by 26.33% to $3.6 million in 2023, then soared by 463.15% to $20.3 million in 2024, then advanced by 5.4% to $21.4 million in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $21.4 million in Q4 2025, $20.3 million in Q4 2024, and $17.6 million in Q3 2024.